CREB1 and neoplasm: Inhibiting cAMP reduces expression of PKA-CREB-dependent genes involved in angiogenesis, inflammation, and tumor growth (Sakamoto & Frank, 2009; Hanahan & Weinberg, 2011) and treatment with the AC5 inhibitor produced dose-dependent reductions in B16F10, LP07, and Lewis lung carcinoma cells (LLC1) cell adhesion and migratory capacity (Fig. 3C,D; Fig. 4B,C; Fig. S2E,F, Supporting information), that is, additional mechanisms meditating tumor growth and progression.